HTMC0435
/ Shanghai Huilun
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 24, 2025
A phase Ib/II study of HTMC0435 plus dose-reduced etoposide and platinum in previously untreated extensive-stage small-cell lung cancer (ES-SCLC)
(ESMO 2025)
- P1/2 | "Pts were administered with HTMC0435 (8 mg or 12 mg twice daily on days 1-21) in combination with etoposide (75 mg/m 2 on days 1-3) and cisplatin (20 mg/m 2 on days 1-3) or carboplatin (AUC 4 on day 1), every 21 days as one cycle. No treatment discontinuations and no deaths occurred due to TRAEs. Conclusions This combination of HTMC0435 plus dose-reduced etoposide and platinum showed promising anti-tumor activity and manageable safety in previously untreated ES-SCLC patients."
P1/2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
June 05, 2025
A dose exploration and dose expansion phase Ib/II study to evaluate oral HTMC0435 tablets in combination with platinum and etoposide in patients with extensive stage small cell lung cancer
(ChiCTR)
- P1/2 | N=74 | Recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University; Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
New P1/2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
April 23, 2025
Efficacy and safety of HTMC0435 combination with temozolomide in relapsed extensive-stage small-cell lung cancer (ES-SCLC): A phase Ib/II study.
(ASCO 2025)
- P1b/2 | "This combination of HTMC0435 and TMZ showed promising anti-tumor activity and manageable safety both in platinum-sensitive and platinum-resistant SCLC patients. Clinical trial information: NCT05728619. Research Sponsor: Shanghai Yidian Pharma."
Clinical • P1/2 data • Anemia • Leukopenia • Lung Cancer • Neutropenia • Oncology • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia
September 28, 2023
HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
(clinicaltrials.gov)
- P1b/2 | N=64 | Recruiting | Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor
1 to 4
Of
4
Go to page
1